Published: February 2011
Giant Hemosiderotic Dermatofibroma: A Case Report and Review of the LiteraturePusztaszeri M.a · Jaquet P.-Y.b · Williamson C.c
aDivision of Clinical Pathology, Geneva University Hospital, Geneva, bGeneral Practitioner, Bassins, and cPathology and Cytology Laboratory, Unilabs-Cytopath, Geneva, Switzerland
Marc Pusztaszeri, MD
Service de Pathologie Clinique (CMU)
1 Rue Michel Servet
CH–1211 Genève 4 (Switzerland)
Tel. +41 223 728 574, E-Mail Marc.Pusztaszeri@hcuge.ch
Do you have an account?
Dermatofibroma is a common benign fibrohistiocytic lesion that usually appears as a slow-growing, firm dermal nodule with a predilection for the legs of middle-aged women. They are usually smaller than 2 cm in diameter. Many histological variants have been described. Generally, the clinical and histological diagnosis is straightforward, but differentiating it from other cutaneous tumors can be difficult in atypical cases and rare variants. Giant dermatofibroma is a rare clinical variant of dermatofibroma and less than 25 cases have been reported. It is characterized essentially by its unusually large size, which often mimics malignant tumors clinically. We first present the case of a giant hemosiderotic dermatofibroma in a 54-year-old patient, who presented with a large ulcerated mass of the left foot which was excised, and then review the literature briefly.
© 2011 S. Karger AG, Basel
Article / Publication Details
Open Access License / Drug Dosage / DisclaimerOpen Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.